
NASDAQHealthcareMedical - Instruments & Supplies
最新資料
US$3.16
−US$0.04 · -1.25%
Nephros, Inc. is a company that specializes in developing and marketing sophisticated water purification solutions across the United States, catering to both the medical and commercial sectors. Its operations are structured into three primary segments: Water Filtration, Pathogen Detection, and Renal Products. Within its Water Filtration division, Nephros offers advanced ultrafiltration products. These are vital in dialysis centers for eradicating biological contaminants from water and bicarbonate concentrate, and are also deployed in hospitals to prevent infections from waterborne pathogens such as Legionella and Pseudomonas. Their utility extends to military installations, outdoor recreation, commercial establishments, and various other healthcare facilities. The Pathogen Detection segment focuses on developing and distributing real-time water testing systems, which deliver critical, actionable data regarding waterborne pathogens. Furthermore, under its Renal Products segment, the company provides medical devices designed for individuals suffering from renal disease, notably including a second-generation hemodiafiltration system tailored for patients with end-stage renal disease. Additionally, Nephros markets a range of water filters under the Nephros and AETHER brands. These filters are engineered not only to enhance water taste and eliminate odors but also to significantly reduce biofilm, bacteria, and scale accumulation in downstream equipment, serving the food service, hospitality, convenience store, and healthcare industries. Established in 1997, Nephros, Inc. maintains its corporate headquarters in South Orange, New Jersey.
一般交易時段
US$3.16
−US$0.04 · -1.25%
盤中時間採用ET。市場資料可能有所延遲。
Nephros, Inc. is a company that specializes in developing and marketing sophisticated water purification solutions across the United States, catering to both the medical and commercial sectors. Its operations are structured into three primary segments: Water Filtration, Pathogen Detection, and Renal Products. Within its Water Filtration division, Nephros offers advanced ultrafiltration products. These are vital in dialysis centers for eradicating biological contaminants from water and bicarbonate concentrate, and are also deployed in hospitals to prevent infections from waterborne pathogens such as Legionella and Pseudomonas. Their utility extends to military installations, outdoor recreation, commercial establishments, and various other healthcare facilities. The Pathogen Detection segment focuses on developing and distributing real-time water testing systems, which deliver critical, actionable data regarding waterborne pathogens. Furthermore, under its Renal Products segment, the company provides medical devices designed for individuals suffering from renal disease, notably including a second-generation hemodiafiltration system tailored for patients with end-stage renal disease. Additionally, Nephros markets a range of water filters under the Nephros and AETHER brands. These filters are engineered not only to enhance water taste and eliminate odors but also to significantly reduce biofilm, bacteria, and scale accumulation in downstream equipment, serving the food service, hospitality, convenience store, and healthcare industries. Established in 1997, Nephros, Inc. maintains its corporate headquarters in South Orange, New Jersey.
日內區間
目前US$3.16
52週區間
目前US$3.16
盤中時間採用ET。市場資料可能有所延遲。
Nephros, Inc. is a company that specializes in developing and marketing sophisticated water purification solutions across the United States, catering to both the medical and commercial sectors. Its operations are structured into three primary segments: Water Filtration, Pathogen Detection, and Renal Products. Within its Water Filtration division, Nephros offers advanced ultrafiltration products. These are vital in dialysis centers for eradicating biological contaminants from water and bicarbonate concentrate, and are also deployed in hospitals to prevent infections from waterborne pathogens such as Legionella and Pseudomonas. Their utility extends to military installations, outdoor recreation, commercial establishments, and various other healthcare facilities. The Pathogen Detection segment focuses on developing and distributing real-time water testing systems, which deliver critical, actionable data regarding waterborne pathogens. Furthermore, under its Renal Products segment, the company provides medical devices designed for individuals suffering from renal disease, notably including a second-generation hemodiafiltration system tailored for patients with end-stage renal disease. Additionally, Nephros markets a range of water filters under the Nephros and AETHER brands. These filters are engineered not only to enhance water taste and eliminate odors but also to significantly reduce biofilm, bacteria, and scale accumulation in downstream equipment, serving the food service, hospitality, convenience store, and healthcare industries. Established in 1997, Nephros, Inc. maintains its corporate headquarters in South Orange, New Jersey.
日內區間
目前US$3.16
52週區間
目前US$3.16
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目(USD) | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 1878.9萬 USD | 1416.2萬 USD | 1423.8萬 USD | 997.5萬 USD | 1021.7萬 USD |
| 銷貨成本 | 730.4萬 USD | 543.9萬 USD | 583.3萬 USD | 524.4萬 USD | 458.4萬 USD |
| 毛利 | 1148.5萬 USD | 872.3萬 USD | 840.5萬 USD | 473.1萬 USD | 563.3萬 USD |
| 研究與開發 | 133.9萬 USD | 90.6萬 USD | 87.3萬 USD | 125.5萬 USD | 149.8萬 USD |
| 銷售、一般及管理費用 | 900萬 USD | 767.6萬 USD | 891.1萬 USD | 759.3萬 USD | 719.5萬 USD |
| 營業費用 | 1033.9萬 USD | 871.7萬 USD | 999.8萬 USD | 906.6萬 USD | 888.5萬 USD |
| 利息收入 | 13.9萬 USD | 9.4萬 USD | 6.4萬 USD | 1.4萬 USD | 1萬 USD |
| 利息支出 | 1000 USD | 1000 USD | 2000 USD | 2萬 USD | 4.1萬 USD |
| 折舊和攤銷 | 13.9萬 USD | 13.7萬 USD | 21.4萬 USD | 35.1萬 USD | 25.2萬 USD |
| 營業利益 | 114.6萬 USD | 6000 USD | −159.3萬 USD | −433.5萬 USD | −325.2萬 USD |
| 淨利 | 119.4萬 USD | 7.4萬 USD | −157.5萬 USD | −738.2萬 USD | −410.7萬 USD |
公司資料更新於 2026年10月8日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動,並非 GoAI 建議。
平均目標
US$4.00
上漲空間 26.58%評級樣本有限,僅4項
| 行動 | 生效日期 | 詳情 | 記錄日期 | 付款日期 |
|---|---|---|---|---|
股票分割 | 2019年7月10日 | 1:9 | — | — |
股票分割 | 2011年3月17日 | 1:20 | — | — |
已生效 2019年7月10日
1:9
已生效 2011年3月17日
1:20
報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI56.03萬0.00%2.3兆 USD0.03%US$379.43-0.42%
Vanguard Extended Market ETFVXF28.99萬0.00%954億 USD0.05%US$231.52-0.84%
iShares Micro-Cap ETFIWC5.38萬0.00%13.33億 USD0.60%US$181.07-1.25%
Dimensional - US Core Equity 2 ETFDFAC2.28萬0.00%882.76億 USD0.21%US$45.015-0.37%
U.S. Core Equity 1 Portfolio ETF Class SharesDCOR1.45萬0.00%454.32億 USD0.17%US$83.855-0.29%
U.S. Vector Equity Portfolio ETF Class SharesDXUV4285.380.00%61.57億 USD0.26%US$67.8231-0.20%
Dimensional - US Sustainability Core 1 ETFDFSU1308.80.00%23.81億 USD0.15%US$47.71-0.44%
Vanguard Morningstar Total Stock Market ETFVTI
Vanguard Extended Market ETFVXF
iShares Micro-Cap ETFIWC
Dimensional - US Core Equity 2 ETFDFAC
U.S. Core Equity 1 Portfolio ETF Class SharesDCOR
U.S. Vector Equity Portfolio ETF Class SharesDXUV
Dimensional - US Sustainability Core 1 ETFDFSUAI 生成內容及延遲市場資料僅供資訊與教育用途,不構成投資建議。